How to Write the Discussion and Conclusion Sections in Clinical Manuscripts

Published on 22/12/2025

Mastering the Discussion and Conclusion Sections of Clinical Trial Manuscripts

In clinical manuscript writing, the discussion and conclusion sections serve as the intellectual core where authors interpret results, address limitations, and underscore implications. These sections bridge your data and its scientific relevance, helping peer reviewers, regulatory agencies, and journal readers understand the study’s contribution.

This tutorial is intended for pharma professionals and clinical trial authors who are responsible for preparing manuscripts for publication or regulatory submissions. Understanding how to write insightful discussions and conclusions can enhance manuscript clarity, quality, and acceptance success.

Table of Contents

Understanding the Role of the Discussion Section:

The discussion is where your data speaks. It is not a repetition of the results section but a critical interpretation of findings. According to EMA standards and journal guidelines, your discussion should address the following:

Context: How do your findings compare to existing literature?
Implications: What do the results mean for practice or science?
Limitations: What could affect the reliability or generalizability?
Future Research: What should be explored next?

The goal is to guide the reader through a thoughtful evaluation of your trial outcomes and their broader relevance. Avoid overstating significance and always consider statistical

and clinical relevance.

How to Structure the Discussion Section:

Follow a clear sequence while writing the discussion. Here’s a recommended outline:

Start with a Summary: Begin with a brief recap of major findings, referencing specific endpoints.
Compare with Existing Literature: Position your results against prior studies or meta-analyses.
Highlight the Interpretation: Explain the meaning of findings, including any unexpected results.
Explain Strengths and Limitations: Be transparent about sample size, population, statistical power, etc.
Suggest Future Directions: Identify unanswered questions or confirmatory study needs.

When applicable, link your findings to pharmaceutical SOP guidelines or validated methodologies to strengthen the discussion.

Common Mistakes to Avoid in the Discussion:

❌ Repeating the results section verbatim
❌ Ignoring conflicting literature or omitting citations
❌ Overgeneralizing or overstating the importance of findings
❌ Failing to discuss study limitations honestly
❌ Lack of structure or disorganized flow

For clinical professionals, clarity and integrity in interpretation are key. Refer to Stability Studies documentation when discussing pharmaceutical endpoints or shelf-life implications.

Writing an Impactful Conclusion Section:

The conclusion serves as the final impression. It should be concise, evidence-based, and aligned with the manuscript’s objective. This section often answers the question: “So what?”

Components of an Effective Conclusion:

Core Finding: Reiterate the main outcome clearly and succinctly.
Scientific Contribution: State how this adds to the field.
Clinical/Practical Relevance: Indicate how it could affect patient care, guidelines, or drug development.
Call to Action: Recommend next steps if needed (e.g., confirmatory studies, regulatory engagement).

The tone should be confident but not exaggerated. Tie back to your pharma regulatory requirements or ICH E3 guidelines where applicable.

Sample Discussion and Conclusion Template:

Use this as a framework when preparing your manuscript:

Discussion
----------
The current study demonstrated that [primary outcome], confirming [reference previous findings] and expanding on [context]. The observed differences may be attributed to [factors]. While our results align with [studies], they differ from [study] due to [reason].

Limitations include [sample size, open-label design, etc.], which may affect [result generalizability].

Further studies evaluating [next question] are warranted.

Conclusion
----------
In conclusion, [intervention] significantly improved [endpoint] compared to [control], suggesting [clinical implication]. These findings support [recommendation] and warrant future investigation in [setting or population].

Checklist for Authors – Discussion and Conclusion:

✅ Key findings are summarized
✅ Comparison with literature is present
✅ Limitations are disclosed honestly
✅ Interpretation does not overreach
✅ Conclusion aligns with study objectives
✅ References and citations are accurate

Use this checklist before submitting your manuscript to ensure completeness and alignment with GMP compliance standards in scientific writing.

Best Practices from Regulatory Perspective:

As per CDSCO and ICH E3 guidelines, conclusions in CSRs (Clinical Study Reports) should reflect results without exaggeration. The discussion section must provide sufficient rationale for efficacy or safety claims, particularly in NDA/ANDA submissions.

Regulatory reviewers often scrutinize this section for scientific judgment and clarity. Ensure consistency across all modules—data tables, graphs, and text must align.

Conclusion:

The discussion and conclusion sections are not mere formalities—they are where your study speaks to the scientific world. For pharmaceutical and clinical professionals, mastering these components is essential for regulatory success, journal acceptance, and scientific impact.

Be honest, be structured, and be concise. Follow established practices and refer to resources such as validation documentation and author guidelines to guide your writing journey.